US EditionTandem agrees to pay $36M to settle Roche patent litigation
Summary by Drug Delivery Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Tandem agrees to pay $36M to settle Roche patent litigation
Tandem Diabetes Care (Nasdaq:TNDM) recently filed an SEC Form 8-K announcing its entry into a patent litigation settlement with Roche. The two companies entered into a settlement, mutual release and cross-license agreement. It resolves all actual or potential patent disputes as of May 21. According to the SEC filing, the settlement relates to Tandem’s t:slim X2 insulin pump and EP Patent No. 2 196 231 B1 (the ’231 patent) and EP Patent No. 1 970…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
